Another Form 483 for Dr. Reddy's: Two Observations at Pydibhimavaram
RDY is trading near its 52-week low of $11.36 (8.0% above the low).
Summary
Dr. Reddy's received a Form 483 with two observations after a USFDA Pre-Approval Inspection of its FTO-11 facility in Pydibhimavaram, Andhra Pradesh, conducted October 5-7, 2026. This is the fourth Form 483 disclosed in three months.
Key Events · Product Development and Regulatory · RDY
-
New Form 483 at Pydibhimavaram Facility
USFDA issued a Form 483 with two observations after a Pre-Approval Inspection (PAI) of the FTO-11 facility in Pydibhimavaram, Andhra Pradesh, conducted October 5-7, 2026.
-
Fourth Form 483 in Three Months
This follows Form 483s at Srikakulam (July 29, three observations), Bachupally (August 17, four observations), and the Mexico API facility (September 14, two observations).
-
PAI Context Raises Approval Risk
A Pre-Approval Inspection is tied to a pending product application, so unresolved observations could delay an upcoming FDA approval.
-
Company Response
Dr. Reddy's states it will address the observations within the stipulated timeline; no details on the nature of the observations were disclosed.
Analysis · RDY · Life Sciences
A Pre-Approval Inspection of Dr. Reddy's FTO-11 facility in Pydibhimavaram, Andhra Pradesh, has resulted in a Form 483 with two observations from the USFDA. This marks the fourth such disclosure in three months, following findings at Srikakulam in July, Bachupally in August, and the Mexico API facility in September. The PAI context is particularly significant—because a Pre-Approval Inspection is tied to a pending product application, unresolved observations could delay an upcoming approval. The company says it will address the observations within the stipulated timeline, but the pattern of repeated regulatory findings across multiple facilities is a growing concern for manufacturing quality oversight.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 28.8% of the 1700 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDY was trading at $12.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.4B. The 52-week trading range was $11.36 to $15.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.